BLM helicase is activated in BCR/ABL leukemia cells to modulate responses to cisplatin

Artur Slupianek, Ewa Gurdek, Mateusz Koptyra, Michal O. Nowicki, Khwaja M. Siddiqui, Joanna Groden, Tomasz Skorski

Research output: Contribution to journalArticlepeer-review

26 Scopus citations

Abstract

Bloom protein (BLM) is a 3′-5′ helicase, mutated in Bloom syndrome, which plays an important role in response to DNA double-strand breaks and stalled replication forks. Here, we show that BCR/ABL tyrosine kinase, which also modulates DNA repair capacity, is associated with elevated expression of BLM. Down-regulation of BLM by antisense cDNA or dominant-negative mutant inhibits homologous recombination repair (HRR) and increases sensitivity to cisplatin in BCR/ABL-positive cells. Bone marrow cells from mice heterozygous for BLM mutation, BLMCin/+, transfected with BCR/ABL display increased sensitivity to cisplatin compared to those obtained from the wild-type littermates. BCR/ABL promotes interactions of BLM with RAD51, while simultaneous overexpression of BLM and RAD51 in normal cells increases drug resistance. These data suggest that BLM collaborates with RAD51 to facilitate HRR and promotes the resistance of BCR/ABL-positive leukemia cells to DNA-damaging agents.

Original languageEnglish
Pages (from-to)3914-3922
Number of pages9
JournalOncogene
Volume24
Issue number24
DOIs
StatePublished - Jun 2 2005
Externally publishedYes

Keywords

  • BCR/ABL
  • BLM
  • Drug resistance
  • Homologous recombination repair
  • RAD51

Fingerprint

Dive into the research topics of 'BLM helicase is activated in BCR/ABL leukemia cells to modulate responses to cisplatin'. Together they form a unique fingerprint.

Cite this